Teva Pharmaceutical details planned stock sale

Teva Pharmaceutical Industries Limited filed a notice of proposed sale of ordinary shares under Rule 144.

Rhea-AI Filing Summary

Teva Pharmaceutical Industries Limited filed a notice of proposed sale of ordinary shares under Rule 144. The filer plans to sell up to 12,827 ordinary shares through Citigroup Global Markets, Inc. on the NYSE, with an approximate sale date of 08/03/2026.

The shares relate to a Restricted Share Unit Award that vested on 08/01/2024 as compensation for services rendered. The filing lists an aggregate market value of $447,350.60 for the shares and references 1,165,296,084 ordinary shares outstanding as context.

Key Figures

Shares to be sold: 12,827 shares Aggregate market value: $447,350.60 Shares outstanding: 1,165,296,084 shares +2 more

5 metrics

Shares to be sold 12,827 shares Ordinary shares proposed for sale under Rule 144

Aggregate market value $447,350.60 Value of 12,827 ordinary shares covered by the notice

Shares outstanding 1,165,296,084 shares Ordinary shares outstanding referenced in the filing

Approximate sale date 08/03/2026 Planned timing for Rule 144 share sale

RSU vesting date 08/01/2024 Restricted Share Unit Award vesting related to the shares

Key Terms

Restricted Share Unit Award Vesting, Services Rendered, Ordinary Shares

3 terms

Restricted Share Unit Award Vesting financial

"Ordinary Shares | 08/01/2024 | Restricted Share Unit Award Vesting |"

Services Rendered financial

"12827 | 08/03/2026 | Services Rendered"

Ordinary Shares financial

"Ordinary Shares | Citigroup Global Markets, Inc 390 Greenwich St"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share sale is disclosed for TEVA in this Form 144 filing?

The filing discloses a proposed sale of up to 12,827 ordinary shares of Teva Pharmaceutical Industries Limited, to be executed through Citigroup Global Markets, Inc. on the NYSE under Rule 144.

When are the TEVA shares expected to be sold under this notice?

The proposed sale is targeted for an approximate date of 08/03/2026. This date reflects when the filer expects to begin selling the 12,827 ordinary shares under the Rule 144 notice.

How were the TEVA shares acquired that are subject to this Form 144?

The shares were acquired through a Restricted Share Unit Award vesting on 08/01/2024. The vesting was in connection with services rendered to Teva Pharmaceutical Industries Limited.

What is the aggregate market value of the TEVA shares to be sold?

The notice lists an aggregate market value of $447,350.60 for the 12,827 ordinary shares proposed to be sold under Rule 144, based on the pricing information used in the filing.

How many TEVA shares were outstanding according to this sale notice?

The document references 1,165,296,084 ordinary shares outstanding. This figure provides context for the size of the 12,827-share proposed sale relative to Teva’s total ordinary shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/03/2026 - 04:00 PM Accepted by SEC EDGAR 08/03/2026 - 04:00 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002026165
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LTD
SEC File Number	001-16174
Address of Issuer	TEVA PHARMACEUTICAL INDUSTRIES LIMITED 124 DVORA HANEVI'A ST. TEL AVIV ISRAEL 6944020
Phone	972 (3) 914-8213
Name of Person for Whose Account the Securities are To Be Sold	Jover Placid
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Executive VP, Chief HR Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Citigroup Global Markets, Inc 390 Greenwich St New York NY 10013	12827	447350.60	1165296084	08/03/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	08/01/2024	Restricted Share Unit Award Vesting	TEVA PHARMACEUTICAL INDUSTRIES LIMITED			12827	08/03/2026	Services Rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks	shares sold were pursuant to an established 10b51 plan adopted in November 2025
Date of Notice	08/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/10/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	CONFORMED SIGNATURE ON FILE
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)